Melanoma: Is immunotherapy of benefit?

Advances in Surgery

Volumn 37, Issue , 2003, Pages 139-169

  Faries, Mark B ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; CANCER CELL DESTRUCTION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CELL KILLING; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOLECULAR RECOGNITION; PROGNOSIS; REVIEW; SURVIVAL RATE; ADULT; AGED; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; IMMUNOTHERAPY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; CANCER VACCINES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141955842     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (109)

1. Coley W: Treatment of inoperable malignant tumors with the toxins of erysipelas and the bacillus prodigiosus. Trans Am Surg Assoc 12:183, 1894.
2. Leyden VV, Blumenthal F: Vorlautige Mitteilungen uber einige Ergebnisse der Krebsforschungauf der medizinischen Klinic. Dr Med Wschr 28:637-641, 1902.
3. Coca A, Dorrance G, Lebredo M: Vaccination in cancer: A report of the results of vaccination therapy as applied to seventy-nine cases of human cancer. J Immunol Exp Ther 13:543-551, 1912.
4. Coca A, Gilman G: The specific treatment of carcinoma. Philos J Sci Med 4:381-392, 1909.
5. Morton D, Eilber F, Malmgren R, et al: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158, 1970.
6. Prehn R, Main J: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769-778, 1957.
7. Morton D: Cancer immunotherapy: An overview, in Najarian J, Delaney J (eds): Advances in Cancer Surgery. Symposia Specialists, Miami, Fla, 1976, pp 89-118.
8. Bodurtha A, Berkelhammer J, Kim Y, et al: A clinical histologic and immunologic study of a case of metastatic melanoma undergoing spontaneous remission. Cancer 37:735-742, 1976.
9. Tuthill R, Unger J, Liu P, et al: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118:504-511, 2002.
10. Clark WJ, Elder D, Guerry D IV, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989.
11. Anbari K, Schuchter L, Bucky L, et al: Melanoma of unknown primary site: Presentation, treatment and prognosis: A single institution study. Cancer 79:1816-1821, 1997.
12. Giuliano A, Cochran A, Morton D: Clinical aspects of unknown primary melanoma. Ann Surg 191:98-104, 1980.
13. Morton D, Wanek L, Nizze J, et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491-499, 1991.
14. Peterson R, Kelley W, Good R: Ataxia-telangiectasia: Its association with a defective thymus, immunological-deficiency disease and malignancy. Lancet 1:1189-1193, 1964.
15. Smith C, Lilly S, Mann L, et al: AIDS-related malignancies. Ann Med 30:323-344, 1998.
16. Penn I, Starzl T: Malignant lymphomas in transplantation patients: A review of the world experience. Internationale Zeitschrift fur Klinische Pharmakologie, Therapie und Toxikologie 3:49-54, 1998.
17. Rodriguez L, Klencke B, Vin-Christian K, et al: Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 138:765-770, 2002.
18. Morton D, Ollila D, Hsueh E, et al: Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49:101-116, 1999.
19. Ollila D, Morton D: Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am 8:183-196, 1998.
20. Hoon D, Wang Y, Dale P, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-2116, 1995.
21. Palmieri G, Strazzullo M, Ascierto P, et al: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol 17:304-311, 1999.
22. Hoon D, Bostick P, Kuo C, et al: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60:2253-2257, 2000.
23. Mackie R, Reid R, Junor B: Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 34:567-568, 2003.
24. King M, Spooner D, Rowlands D: Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: A case report and a review of the literature. Clin Oncol (R Coll Radiol) 13:466-469, 2001.
25. Wang T, Lowe L, Smith JW II, et al: Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 24:915-919, 1998.
26. Nathanson L: Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 44:67-76, 1976.
27. Bulkley G, Cohen M, Banks P, et al: Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile. Cancer 36:485-494, 1975.
28. Nasi M, Meyers M, Livingston P, et al: Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 7:S155-S162, 1997.
29. Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al: Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 6:1636-1648, 1988.
30. Cascinelli N, Rumke P, MacKie R, et al: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28:282-286, 1989.
31. Eilber F, Morton D, Holmes E, et al: Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma. N Engl J Med 294:237-240, 1976.
32. Hsueh E, Gupta R, Yee R, et al: Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol 7:232-238, 2000.
33. Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991.
34. Kawakami Y, Eliyahu S, Delgado C, et al: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462, 1994.
35. Busam K, Chen Y, Old L, et al: Expression of melan-A (MART-1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 22:976-982, 1998.
36. Riker A, Cormier J, Panelli M, et al: Immune selection following antigen specific immunotherapy of melanoma. Surgery 126:112-120, 1999.
37. Zeng G, Wang X, Robbins P, et al: CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO- presented by a prevalent HLA-DP4 allele: Association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A 98:3964-3969, 2001.
38. Heath W, Carbone F: Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1:126-34, 2001.
39. Eilber F, Morton D: Sarcoma-specific antigens: Detection by complement fixation with serum from sarcoma patients. J Natl Cancer Inst 44:651-656, 1970.
40. Berd D, Maguire H, Schuchter L, et al: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-2370, 1997.
41. Rosenberg S, Rapp H: Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60:419-430, 1976.
42. Morton DL, Eilber FR, Holmes EC, et al: BCA immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643, 1974.
43. Mastrangelo M, Bellet R, Berkelhammer J, et al: Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 36:1305-1308, 1975.
44. Cohen M, Jessup J, Felix E, et al: Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective trial of intralesional bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 41:2456-2463, 1978.
45. von Wussow P, Block B, Hartmann F, et al: Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61:1071-1074, 1988.
46. Ridolfi L, Ridolfi R: Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 49:335-359, 2002.
47. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al: Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients. J Eur Acad Dermatol Venereol 15:218-223, 2001.
48. Si Z, Hersey P, Coates A: Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6:247-255, 1996.
49. Keilholz U, Eggermont A: The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. Oncology 58:89-95, 2000.
50. Atkins M, Lotze M, Dutcher J, et al: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999.
51. Rosenberg S, Yang J, White D, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 228:307-319, 1998.
52. Schiller J, Pugh M, Kirkwood J, et al: Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: An innovative study design. Clin Cancer Res 2:29-36, 1996.
53. Mughal T, Thomas M, Robinson W: Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology 48:365-368, 1991.
54. Kirkwood J, Ibrahim J, Sondak V, et al: High and low dose interferon alpha-2b in high-risk melanoma: First analysis of intergroup trial E1690 /S9111/C9190. J Clin Oncol 18:2444-2458, 2000.
55. Sondak V, Ross M, Schuchter L: Early stage (I,II,III) melanoma. Curr Treat Options Oncol 2:183-191, 2001.
56. O'Day S, Kim C, Reintgen D: Metastatic melanoma: Chemotherapy to biochemotherapy. Cancer Control 9:31-38, 2002.
57. O'Day S, Gammon G, Boasberg P, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17:2752-2761, 1999.
58. Rosenberg S, Yannelli J, Yang J, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159-1166, 1994.
59. Goedegebuure P, Douville L, Li H, et al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 13:1939-1949, 1995.
60. Salgaller M, Marincola F, Cormier J, et al: Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res 56:4749-4757, 1996.
61. Jager E, Ringhoffer M, Dienes H, et al: Granulocyte-macrophage-colony- stimulating factor enchances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54-62, 1996.
62. Jager E, Ringhoffer M, Altmannsberger M, et al: Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142, 1997.
63. Rosenberg S, Yang J, Schwartzentruber D, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998.
64. Nestle F, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 4:269-270, 1998.
65. Panelli M, Wunderlich J, Jeffries J, et al: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes from the melanoma-associated antigens MART-1 and gp100. J Immunother 23:487-498, 2000.
66. Lau R, Wang F, Jeffery G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001.
67. Bystryn J, Zeleniuch-Jacquotte A, Oratz R, et al: Double-blind trial of a polyvalent, shed-antigen melanoma vaccine. Clin Cancer Res 7:1882-1887, 2001.
68. Ravindranath M, Bauer P, Cornillez-Ty C, et al: Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J Immunol Methods 197:51-67, 1996.
69. Ravindranath M, Morton D, Irie R: An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-3897, 1989.
70. Kirkwood J, Ibrahim J, Sosman J, et al: High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine patients with resected stage IIB-III melanoma: Results of intergoup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001.
71. Wallack M, Scoggin S, Sivanandham M: Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 59:227-233, 1992.
72. Wallack M, Sivanandham M, Balch C, et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187:69-77, 1998.
73. Hersey P, Coates A, McCarthy W, et al: Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 20:4148-4190, 2002.
74. Sondak V, Liu P, Tuthill R, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20:2058-2066, 2002.
75. Mitchell M: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623-635, 1998.
76. Sosman J, Unger J, Liu P, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075, 2002.
77. Berd D: M-Vax: An autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2:335-342, 2002.
78. Berd D, Sato T, Cohn H, et al: Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 94:531-539, 2001.
79. Chi D, Merchant R, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997.
80. Cheresh D, Reisfeld R, Varki A: O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 225:844-846, 1984.
81. Doi F, Chi D, Charuworn B, et al: Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer 65:454-459, 1996.
82. Euhus D, Gupta R, Morton D: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 29:247-254, 1989.
83. Gaugler B, Eynde B, Bruggen P, et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930, 1994.
84. Gupta R, Morton D: Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 70:993-1004, 1983.
85. Gupta R, Morton D: Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line. J Natl Cancer Inst 72:83-92, 1984.
86. Hoon D, Yuzuki D, Hayashida M, et al: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154:730-737, 1995.
87. Hsueh E, Gupta R, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998.
88. Huang S, Okamoto T, Morton D, et al: Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 111:662-667, 1998.
89. Jones R, Kelley M, Gupta R, et al: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 3:437-445, 1996.
90. Kawakami Y, Eliyahu S, Delgado C, et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519, 1994.
91. Morioka N, Kikumoto Y, Hoon D, et al: A decapeptide (Gln-Asp-Leu-Thr-Met- Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 153:5650-5658, 1994.
92. Morton D, Foshag L, Hoon D, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992.
93. Nishinaka Y, Ravindranath M, Irie R: Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res 56:5666-5671, 1996.
94. Okamoto T, Irie R, Fujii S, et al: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-1039, 1998.
95. Ravindranath M, Tsuchida T, Morton D, et al: Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 67:3029-3035, 1991.
96. Tai T, Cahan L, Tsuchida T, et al: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985.
97. Tai T, Paulson J, Cahan D, et al: Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A 80:5392-5396, 1983.
98. Takahashi T, Conforti A, Kikumoto Y, et al: Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. J Clin Immunol 18:299-305, 1998.
99. Tsuchida T, Saxton R, Irie R: Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 78:55-60, 1987.
100. Tsuchida T, Saxton R, Morton D, et al: Gangliosides of human melanoma. Cancer 63:1166-1174, 1989.
101. Wong J, Aguero B, Gupta R, Morton D. Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients. Cancer Immunol Immunother 27:142-146, 1988.
102. Wong J, Xu S, Gupta R, et al: Tumor-associated antigen immune complexes: A potential marker of recurrent melanoma. Arch Surg 125:187-191, 1990.
103. Jones P, Sze L, Liu P, et al: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981.
104. Morton D, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244, 1996.
105. Hsueh E, Essner R, Foshag L, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549-4554, 2002.
106. Barth A, Hoon D, Foshag L, et al: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54:3342-3345, 1994.
107. DiFronzo L, Gupta R, Essner R, et al: Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242, 2002.
108. Chung M, Gupta R, Hsueh E, et al: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 21:313-319, 2003.
109. Morton D, Hsueh E, Essner R, et al: Prolonged survival in patients receiving active immunotherapy with Canvaxin therapeutic vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438-448, 2002.